- Home
- ZYME vs BALY Comparison
ZYME vs BALY Comparison
Compare ZYME & BALY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- BALY
- Stock Information
- Founded
- ZYME 2003
- BALY 2004
- Country
- ZYME United States
- BALY United States
- Employees
- ZYME 286
- BALY 10000
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- BALY Hotels/Resorts
- Sector
- ZYME Health Care
- BALY Consumer Discretionary
- Exchange
- ZYME Nasdaq
- BALY Nasdaq
- Market Cap
- ZYME 739.6M
- BALY 737.4M
- IPO Year
- ZYME 2017
- BALY N/A
- Fundamental
- Price
- ZYME $11.53
- BALY $18.04
- Analyst Decision
- ZYME Buy
- BALY Hold
- Analyst Count
- ZYME 6
- BALY 7
- Target Price
- ZYME $19.50
- BALY $18.00
- AVG Volume (30 Days)
- ZYME 833.8K
- BALY 363.4K
- Earning Date
- ZYME 05-08-2025
- BALY 02-19-2025
- Dividend Yield
- ZYME N/A
- BALY N/A
- EPS Growth
- ZYME N/A
- BALY N/A
- EPS
- ZYME N/A
- BALY N/A
- Revenue
- ZYME $76,304,000.00
- BALY $2,481,783,000.00
- Revenue This Year
- ZYME $26.29
- BALY $3.06
- Revenue Next Year
- ZYME $75.78
- BALY N/A
- P/E Ratio
- ZYME N/A
- BALY N/A
- Revenue Growth
- ZYME 0.38
- BALY 2.80
- 52 Week Low
- ZYME $7.97
- BALY $9.74
- 52 Week High
- ZYME $17.70
- BALY $18.38
- Technical
- Relative Strength Index (RSI)
- ZYME 49.31
- BALY 60.77
- Support Level
- ZYME $10.69
- BALY $14.67
- Resistance Level
- ZYME $11.48
- BALY $15.79
- Average True Range (ATR)
- ZYME 0.78
- BALY 2.04
- MACD
- ZYME 0.10
- BALY 0.58
- Stochastic Oscillator
- ZYME 81.57
- BALY 97.51
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About BALY Bally's Corporation
Ballys Corp is a gaming, hospitality, and entertainment company with a portfolio of casinos and resorts and a growing omnichannel presence. It provides customers with physical and interactive entertainment and gaming experiences, including traditional casino offerings, iGaming, online bingo, sportsbook, and free-to-play (F2P) games. The company owns and operates, several casinos across the United States, one golf course in New York, one horse racetrack in Colorado, and Aspers Casino in the United Kingdom. Its Interactive International division, an interactive gaming operator concentrated in Europe, operates a lottery management and services business. The company's reportable segments are Casinos and Resorts, which derive key revenue, International Interactive and North America Interactive.